Gland Pharma Limited — Important, 16-01-2025: Updates

The US FDA has concluded its Good Manufacturing Practices (GMP) inspection at the Dundigal Facility in Hyderabad. The company received the Establishment Inspection Report (EIR), signaling that all audit processes have been satisfactorily completed. This positive development enhances Gland Pharma's operational credibility and could facilitate smoother product approvals moving forward, potentially improving growth outlook. Investors should view this as a strengthening of compliance and quality assurance at the facility, positioning the company favorably in the competitive pharmaceutical landscape. Watch closely for any future developments that may arise from this inspection outcome.